Blue Bell Private Wealth Management’s GT Biopharma GTBP Stock Holding History

Blue Bell Private Wealth Management’s Portfolio GTBP Stock Details GTBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-10	Closed	-$6	–	741
2025 Q3	$6	Hold	10	–	–	﹤0.01%	734
2025 Q2	$36	Hold	10	–	–	﹤0.01%	726
2025 Q1	$22	Hold	10	–	–	﹤0.01%	717
2024 Q4	$31	Hold	10	–	–	﹤0.01%	674
2024 Q3	$23	Hold	10	–	–	﹤0.01%	685
2024 Q2	$28	Hold	10	–	–	﹤0.01%	713
2024 Q1	$44	Hold	10	–	–	﹤0.01%	720
2023 Q4	$77	Hold	10	–	–	﹤0.01%	714
2023 Q3	$72	Hold	10	–	–	﹤0.01%	673
2023 Q2	$94	Hold	10	–	–	﹤0.01%	678
2023 Q1	$165	Hold	10	–	–	﹤0.01%	655
2022 Q4	$266	Hold	10	–	–	﹤0.01%	680
2022 Q3	$1K	Hold	10	–	–	﹤0.01%	675
2022 Q2	$1K	Hold	10	–	–	﹤0.01%	723
2022 Q1	$1K	Hold	10	–	–	﹤0.01%	789
2021 Q4	$1K	Buy	+10	New	+$1.5K	﹤0.01%	776

Other funds holding GTBP

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

SRL

Scientech Research LLC Jersey City, New Jersey $120M AUM 73.62% 1-Year Est. Return

SWM

SeaCrest Wealth Management Purchase, New York $903M AUM 47.26% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

IWC

Integrated Wealth Concepts Waltham, Massachusetts $12.5B AUM 18.49% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CMP

Coston McIsaac & Partners Bar Harbor, Maine $443M AUM 6.68% 1-Year Est. Return

Caitlin John Brighton, Michigan $167M AUM 23.74% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Blue Bell Private Wealth Management's GTBP Position: Q4 2025 in Review

Blue Bell Private Wealth Management sold out of GT Biopharma (GTBP) in Q4 2025, closing a stake of 10 shares — an estimated $6 sold.

Blue Bell Private Wealth Management first reported a position in GTBP in Q4 2021 and held it in 16 quarters. The position peaked at $1K in Q3 2022. 38 funds tracked by Wall St. Rank hold GTBP as of Q4 2025.

Blue Bell Private Wealth Management reported no remaining GT Biopharma position as of Q4 2025 after selling out during the quarter.
Blue Bell Private Wealth Management sold 10 GT Biopharma shares in Q4 2025, an estimated $6.
Blue Bell Private Wealth Management first reported a position in GT Biopharma in Q4 2021 and held it in 16 quarters.
Blue Bell Private Wealth Management's GT Biopharma position peaked at $1K in Q3 2022.
38 funds tracked by Wall St. Rank held GT Biopharma as of Q4 2025.

Based on Blue Bell Private Wealth Management's 13F filing for Q4 2025, filed 9 Feb 2026.